FrancophonIA/ELRC3.0 huggingface dataset:
English: However, the data presented by the MAH indicate that there are no significant changes in the posttranslational modifications, aggregation profile, specific activity or excipients since MA of Kogenate Bayer that might have increased the risk for inhibitor development over time.
Maltese: Madankollu, id-dejta ppreżentata mill-MAH tindika li m'hemmx tibdil sinifikanti fil-modifiki posttraduzzjonali, fil-profil ta' aggregazzjoni, l-attività speċifika jew fl-eċċipjenti millawtorizzazzjoni għat-tqegħid fis-suq ta' Kogenate Bayer li maż-żmien seta' jżid ir-riskju għalliżvilupp ta' inibituri.
English: International non-proprietary name (INN): doxycycline hyclate
Maltese: Isem internazzjonali komuni (INN): doxycycline hyclate
English: Oral explanations were given on 5 March 2013.
Maltese: Fil-5 ta' Marzu 2013 kienu mogħtija spjegazzjonijiet orali.
English: The reference Member State (RMS) is the United Kingdom and 12 concerned Member States (CMS) are involved: Austria, Czech Republic, Estonia, Finland, France, Germany, Greece, Italy, Latvia, the Netherlands, Slovakia and Spain.
Maltese: L-Istat Membru ta' riferiment (SMR) huwa r-Renju Unit u huma involuti 12-il Stat Membru kkonċernati (SMK): l-Awstrija, ir-Repubblika Ċeka, l-Estonja, il-Finlandja, Franza, il-Ġermanja, il-Greċja, l-Italja, il-Latvja, il-Pajjiżi l-Baxxi, is-Slovakkja u Spanja.
English: The Committee appointed Mr J. Schefferlie as rapporteur and Ms H. Jukes as co-rapporteur.
Maltese: Schefferlie bħala rapporteur u lis-Sinjura H. Jukes bħala ko-rapporteur.
English: On 22 March 2013, Eurovet Animal Health BV notified the Agency of their intention to request a reexamination of the CVMP opinion of 7 March 2013.
Maltese: Fit-22 ta' Marzu 2013, Eurovet Animal Health BV innotifikaw lill-Aġenzija bl-intenzjoni tagħhom li jitolbu eżaminazzjoni mill-ġdid tal-opinjoni tas-CVMP tas-7 ta' Marzu 2013.
English: Soludox 500 mg/g powder for use in drinking water for pigs and chickens contains doxycycline hyclate as active ingredient.
Maltese: Soludox 500 mg/g trab għall-użu fl-ilma tax-xorb għall-majjali u t-tiġieġ fih doxycycline hyclate bħala sustanza attiva.
English: It is indicated in chickens to reduce mortality, morbidity, and clinical signs and to reduce lesions due to Pasteurellosis caused by Pasteurella multocida or to reduce morbidity and lesions in respiratory infections caused by Ornithobacterium rhinotracheale (ORT).
Maltese: Huwa indikat fit-tiġieġ biex inaqqas il-mortalità, il-morbidità, u sinjali kliniċi u biex inaqqas il-leżjonijiet minħabba Pasteurellosis ikkawżata mill-Pasteurella multocida jew biex inaqqas ilmorbidità u l-leżjonijiet f'infezzjonijiet respiratorji kkawżati mill-Ornithobacterium rhinotracheale (ORT).
English: Written explanations were provided by the marketing authorisation holder on 8 January 2013.
Maltese: Id-detentur tal-awtorizzazzjoni għat-tqegħid fissuq ipprovda spjegazzjonijiet bil-miktub fit-8 ta' Jannar 2013.
English: The detailed grounds for the re-examination request were submitted by Eurovet Animal Health BV on 26 April 2013.
Maltese: Ir-raġunijiet dettaljati għat-talba għal eżaminazzjoni mill-ġdid kienu ppreżentati minn Eurovet Animal Health BV fis-26 ta' April 2013.
English: The worksharing procedure (UK/V/xxxx/WS/006) involving Soludox 500 mg/g powder for use in drinking water for pigs and chickens (NL/V/0141/001/WS/002) and Soludox 500 mg/g powder for use in drinking water for pigs and chickens (UK/V/0349/001/WS/002) started on 6 January 2012.
Maltese: Il-proċedura ta' kondiviżjoni tax-xogħol (UK/V/xxxx/WS/006) li kienet tinvolvi Soludox 500 mg/g trab għall-użu fl-ilma tax-xorb għall-majjali u t-tiġieġ (NL/V/0141/001/WS/002) u Soludox 500 mg/g trab għall-użu fl-ilma tax-xorb għall-majjali u t-tiġieġ (UK/V/0349/001/WS/002) bdiet fis-6 ta' Jannar 2012.
English: The marketing authorisation holder, Eurovet Animal Health BV submitted an application for a type II variation to shorten the withdrawal period in chickens to 6 days for Soludox 500 mg/g powder for use in drinking water for pigs and chickens and associated names, which has been subject to a worksharing procedure by the CMDv according to Article 20 of Commission Regulation (EC) No 1234/2008.
Maltese: Id-detentur tal-awtorizzazzjoni għat-tqegħid fis-suq, Eurovet Animal Health BV issottometta applikazzjoni għal varjazzjoni tip II sabiex jitnaqqas il-perjodu tal-irtirar fit-tiġieġ għal 6 ijiem għal Soludox 500 mg/g trab għall-użu fl-ilma tax-xorb għall-majjali u t-tiġieġ u ismijiet assoċjati, li kien soġġett għal proċedura ta' kondiviżjoni tax-xogħol mis-CMDv skont l-Artikolu 20 tar-Regolament talKummissjoni (KE) Nru 1234/2008.
English: On 12 June 2013 the CVMP adopted a final opinion confirming the recommendation included in its opinion of 7 March 2013, that the variation of the marketing authorisations for Soludox 500 mg/g powder for use in drinking water for pigs and chickens (NL/V/0141/001/WS/002) and Soludox 500 mg/g powder for use in drinking water for pigs and chickens (UK/V/0349/001/WS/002) can be granted and a withdrawal period of 9 days is appropriate for chickens for the dose of 20 mg/kg bw for 4 consecutive days.
Maltese: Fit-12 ta' Ġunju 2013 is-CVMP adotta opinjoni finali li kkonfermat ir-rakkomandazzjoni inkluża flopinjoni tiegħu tas-7 ta' Marzu 2013, li l-varjazzjoni tal-awtorizzazzjonijiet għat-tqegħid fis-suq għal Soludox 500 mg/g trab għall-użu fl-ilma tax-xorb għall-majjali u t-tiġieġ (NL/V/0141/001/WS/002) u Soludox 500 mg/g trab għall-użu fl-ilma tax-xorb għall-majjali u t-tiġieġ (UK/V/0349/001/WS/002) tista' tingħata u li perjodu tal-irtirar ta' 9 ijiem huwa adattat għat-tiġieġ għad-doża ta' 20 mg/kg bw għal 4 ijiem wara xulxin.
English: The CVMP concluded a withdrawal period of 9 days is appropriate for chickens for the dose of 20 mg/kg bw for 4 consecutive days.
Maltese: Is-CVMP ikkonkluda li perjodu tal-irtirar ta' 9 ijiem huwa adattat għat-tiġieġ għad-doża ta' 20 mg/kg bw għal 4 ijiem wara xulxin.
English: There are two authorised dosages: 10 mg/kg bw for 4 consecutive days, for which the withdrawal period is 3 days, and 20 mg/kg bw for 4 consecutive days for which the withdrawal period is 12 days.
Maltese: Hemm żewġ dożaġġi awtorizzati: 10 mg/kg bw għal 4 ijiem wara xulxin, li għalih il-perjodu talirtirar huwa ta' 3 ijiem, u 20 mg/kg bw għal 4 ijiem wara xulxin li għalih il-perjodu tal-irtirar huwa ta' 12-il jum.
English: Based on the evaluation of the available data the CVMP adopted, on 7 March 2013, an opinion recommending the granting of the variation of the marketing authorisations for Soludox 500 mg/g powder for use in drinking water for pigs and chickens (NL/V/0141/001/WS/002) and Soludox 500 mg/g powder for use in drinking water for pigs and chickens (UK/V/0349/001/WS/002).
Maltese: Abbażi tal-evalwazzjoni tad-dejta disponibbli, is-CVMP, fis-7 ta' Marzu 2013 adotta opinjoni li tirrakkomanda l-għoti tal-varjazzjoni tal-awtorizzazzjonijiet għat-tqegħid fis-suq għal Soludox 500 mg/g trab għall-użu fl-ilma tax-xorb għall-majjali u t-tiġieġ (NL/V/0141/001/WS/002) u Soludox 500 mg/g trab għall-użu fl-ilma tax-xorb għall-majjali u t-tiġieġ (UK/V/0349/001/WS/002).
English: Opinion following an Article 131 referral for Soludox 500 mg/g powder for use in drinking water for pigs and chickens and associated names
Maltese: Opinjoni wara riferiment għall-Artikolu 130F għal Soludox 500 mg/g trab għall-użu flilma tax-xorb għall-majjali u t-tiġieġ u ismijiet assoċjati
English: During its meeting of 9-11 April 2013 the CVMP appointed Prof. C. Friis as the rapporteur and Dr M. Holzhauser-Alberti as the co-rapporteur for the re-examination procedure.
Maltese: Holzhauser-Alberti bħala l-ko-rapporteur għall-proċedura ta' eżaminazzjoni mill-ġdid.
English: On 30 October 2012, the reference Member State, the United Kingdom, notified the European Medicines Agency that the CMD(v) had failed to reach an agreement and referred the matter to the CVMP pursuant to Article 13(2) of Commission Regulation (EC) No. 1234/2008.
Maltese: Fit-30 ta' Ottubru 2012, l-Istat Membru ta' riferiment, ir-Renju Unit, innotifika lill-Aġenzija Ewropea għall-Mediċini li s-CMD(v) kien naqas milli jilħaq ftehim dwar il-prodott u rrefera l-kwistjoni lis-CVMP skont l-Artikolu 13(2) tar-Regolament tal-Kummissjoni (KE) Nru 1234/2008.
English: The re-examination procedure started on 27 April 2013.
Maltese: Il-proċedura ta' eżaminazzjoni mill-ġdid bdiet fis-27 ta' April 2013.
English: Ref. EMA/CHMP/77992/2010 EMEA/H/A-29/1084
Maltese: Dok. ta' Ref. EMA/CHMP/77992/2010 EMEA/H/A-29/1084
English: London, 22 October 2009 rev. Doc.
Maltese: Londra, 22 ta' Ottubru 2009 rev.
English: Re-examination
Maltese: Rieżaminazzjoni
English: Article 29 of Directive 2001/83/EC as amended, referral on the grounds of potential serious risk to public health
Maltese: L-Artikolu 29 tad-Direttiva 2001/83/KE kif emendata, referenza għar-raġunijiet ta' riskju serju potenzjali għassaħħa pubblika
English: Gram-positive bacteria include bacteria such as staphylocci (Staphylococcus aureus), streptococci (Streptococcus pneumoniae), Listeria, Clostridium difficile.
Maltese: Batterji Gram-pożittivi jinkludu batterji bħalma huma staphylocci (Staphylococcus aureus), streptokokki (Streptococcus pneumoniae), Listeria, Clostridium difficile.
English: Teicoplanin Hospira is a generic medicine based on a ‘reference medicine' authorised in Germany (Targocid 400 mg).
Maltese: Teicoplanin Hospira hija mediċina ġenerika bbażata fuq ‘mediċina ta' referenza' awtorizzata filĠermanja (Targocid 400 mg).
English: Teicoplanin Hospira is an antibiotic.
Maltese: Teicoplanin Hospira huwa antibijotiku.
English: Questions and answers on the referral for Teicoplanin Hospira powder and solvent for injection containing 200 or 400 mg teicoplanin
Maltese: Mistoqsijiet u tweġibiet dwar ir-referenza għal Teicoplanin Hospira trab u solvent għal injezzjoni li fih 200 jew 400 mg teicoplanin
English: The active substance in Teicoplanin Hospira, teicoplanin, is an antibiotic that belongs to the group ‘glycopeptides'.
Maltese: Is-sustanza attiva f'Teicoplanin Hospira, teicoplanin, hija antibijotiku li jappartjeni għall-grupp ta' ‘glikopeptidi'.
English: Hospira UK Limited submitted Teicoplanin Hospira to the German Regulatory Agency for a decentralised procedure.
Maltese: Hospira UK Limited issottomettiet Teicoplanin Hospira lill-Aġenzija Regolatorja Ġermaniża għal proċedura deċentralizzata.
English: Medicines are bioequivalent when they produce the same levels of the active substance in the body.
Maltese: Mediċini jkunu bijoekwivalenti meta jipproduċu listess livelli tas-sustanza attiva fil-ġisem.
English: Referral start date:
Maltese: Il-bidu tad-data ta' riferiment:
English: What is Teicoplanin Hospira?
Maltese: X'inhu Teicoplanin Hospira?
English: On 25 June 2009, the European Medicines Agency (EMEA) completed an arbitration procedure following a disagreement among Member States of the European Union regarding the authorisation of the medicine Teicoplanin Hospira.
Maltese: Fil-25 ta' Ġunju 2009, l-Aġenzija Ewropea tal-Mediċini (EMEA) temmet proċedura ta' arbitraġġ wara nuqqas ta' qbil fost Stati Membri tal-Unjoni Ewropea fir-rigward tal-awtorizzazzjoni tal-mediċina Teicoplanin Hospira.
English: This is a procedure when one Member State (the ‘reference Member State', in this instance Germany) assesses a medicine with a view of granting a marketing authorisation that will be valid in this country as well as in other Member States (the ‘concerned Member States', in this instance Austria, Ireland, Italy, Portugal, Spain and the United Kingdom).
Maltese: Din hija proċedura meta Stat Membru (l-‘Istat Membru ta' referenza', f'dan il-każ il-Ġermanja) jivvaluta mediċina bil-għan li din tingħata awtorizzazzjoni għat-tqegħid fis-suq li tkun valida f'dan il-pajjiż kif ukoll fi Stati Membri oħrajn (l-‘Istati Membri kkonċernati', f'dan il-każ, l-Awstrija, l-Irlanda, l-Italja, il-Portugall, Spanja u r-Renju Unit).
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of Teicoplanin Hospira do not outweigh its risks, and the marketing authorisation cannot be granted in Germany and in other Member States of the EU (Austria, Ireland, Italy, Portugal, Spain and the United Kingdom).
Maltese: Il-Kumitat tal-Aġenzija għall-Prodotti Mediċinali għall-Użu mill-Bniedem (CHMP) ikkonkluda li l-benefiċċji ta' Teicoplanin Hospira ma jisbqux ir-riskji tiegħu, u lawtorizzazzjoni għat-tqegħid fis-suq ma tistax tingħata fil-Ġermanja u fi Stati Membri oħrajn tal-UE (l-Awstrija, l-Irlanda, l-Italja, il-Portugall, Spanja u r-Renju Unit).
English: After having considered the grounds for this request, the CHMP re-examined the initial opinion, and confirmed the recommendation for the refusal of the marketing authorisation on 22 October 2009.
Maltese: Wara li kkunsidra r-raġunijiet għal din it-talba, is-CHMP eżamina mill-ġdid l-opinjoni inizjali u kkonferma r-rakkomandazzjoni għar-rifjut tal-awtorizzazzjoni għat-tqegħid fis-suq fit-22 ta' Ottubru 2009.
English: The grounds for the referral were concerns from Ireland and the United Kingdom that Teicoplanin Hospira had not been shown to be bioequivalent to Targocid.
Maltese: Ir-raġunijiet għar-referenza kienu tħassib mill-Irlanda u mir-Renju Unit li Teicoplanin Hospira ma ntweriex li huwa bijoekwivalenti għal Targocid.
English: There were also concerns that the composition of the teicoplanin in Teicoplanin Hospira was different to that in Targocid, with a potential impact on the effectiveness of the medicine.
Maltese: Kien hemm ukoll tħassib li l-kompożizzjoni ta' teicoplanin f'Teicoplanin Hospira kienet differenti minn dik f'Targocid, b'impatt potenzjali fuq l-effikaċja tal-mediċina.
English: Teicoplanin Hospira can only be used in patients who cannot receive penicillin or cephalosporins antibiotics, or if these antibiotics have stopped working or the infection is due to a Staphylococcus that is resistant to other antibiotics.
Maltese: Teicoplanin Hospira jista' jintuża biss f'pazjenti li ma jistgħux jirċievu peniċillina jew antibijotiċi tat-tip cephalosporins, jew jekk dawn l-antibijotiċi jkunu waqfu jaħdmu jew jekk linfezzjoni tkun dovuta għal Staphylokokkus li huwa reżistenti għal antibijotiċi oħrajn.
English: This is because teicoplanin in Teicoplanin Hospira is made by fermentation, using a bacterium called Actinoplanes to produce the antibiotic.
Maltese: Dan minħabba li teicoplanin f'Teicoplanin Hospira huwa magħmul minn fermentazzjoni, permezz ta' batterju msejjaħ Actinoplanes biex jipproduċi l-antibijotiku.
English: Why was Teicoplanin Hospira reviewed?
Maltese: Għaliex ġie rivedut Teicoplanin Hospira?
English: The company that makes Teicoplanin Hospira, Hospira UK Limited, requested a re-examination of the opinion.
Maltese: Il-kumpanija li tagħmel Teicoplanin Hospira, Hospira UK Limited, talbet li jsir eżami mill-ġdid talopinjoni.
English: Company responses provided on: 23 January 2009 and 27 May 2009
Maltese: 4 ta' Settembru 2009
English: Opinion date:
Maltese: Valutazzjoni inizjali
English: However, the Member States were not able to reach an agreement and the German Regulatory Agency referred the matter to the CHMP for arbitration on 8 October 2008.
Maltese: Madankollu, l-Istati Membri ma setgħux jilħqu ftehim u l-Aġenzija Regolatorja Ġermaniża rreferiet ilkwistjoni lis-CHMP għal arbitraġġ fit-8 ta' Ottubru 2008.
English: It is use to treat patients with serious infections due to Grampositive bacteria.
Maltese: Jintuża biex jikkura pazjenti b'infezzjonijiet serji dovuti għal batterji Gram-pożittivi.
English: Gabapentin - Dysphagia (EPITT no 19296)
Maltese: Gabapentin - Disfaġja (EPITT nru 19296)
English: Interference with clinical laboratory tests
Maltese: Interferenza mat-testijiet kliniċi fil-laboratorju
English: Biotin - Interference with clinical laboratory tests (EPITT no 19156)
Maltese: Bijotina - Interfernza mat-testijiet kliniċi fil-laboratorju (EPITT nru 19156)
English: [Product name] contains <quantity> biotin per <dose unit>.
Maltese: [Isem tal-prodott] fih <kwantità> bijotina għal kull <unità tad-dożaġġ>.
English: Adopted at the 14-17 January 2019 PRAC
Maltese: Adottati fil-PRAC ta' bejn l-14-17 ta' Jannar 2019
English: Undesirable effects Gastrointestinal disorders Uncommon: dysphagia
Maltese: Effetti mhux mixtieqa Disturbi gastrointestinali
English: For medicinal products for oral use containing ≥150 microgram biotin per dose unit and medicinal products for parenteral use containing ≥60 microgram biotin per dose unit
Maltese: Għal prodotti mediċinali għal użu orali li fihom ≥150 mikrogramma ta' bijotina għal kull unità taddożaġġ u prodotti mediċinali għal użu parenterali li fihom ≥60 mikrogramma ta' bijotina għal kull unità tad-dożaġġ
English: When interpreting results of laboratory tests, possible biotin interference has to be taken into consideration, especially if a lack of coherence with the clinical presentation is observed (e.g. thyroid test results mimicking Graves' disease in asymptomatic patients taking biotin or false negative troponin test results in patients with myocardial infarction taking biotin).
Maltese: Meta jkunu qed jiġu interpretati r-riżultati tat-testijiet fil-laboratorju, trid titqies l-interferenza possibbli tal-bijotina, speċjalment jekk jiġi osservat nuqqas ta' koerenza malpreżentazzjoni klinika (eż. riżultati tat-testijiet tat-tirojde li jimitaw il-marda ta' Graves f'pazjenti
English: • Difficulty swallowing
Maltese: Mhux komuni: disfaġja
English: Your doctor may ask you to stop taking [Product name] before performing laboratory tests.
Maltese: Ittabib tiegħek jista' jitolbok li tieqaf tieħu [Isem tal-prodott] qabel twettaq testijiet fil-laboratorju.
English: Biotin may interfere with laboratory tests that are based on a biotin/streptavidin interaction, leading to either falsely decreased or falsely increased test results, depending on the assay.
Maltese: Il-bijotina tista' tinterferixxi ma' testijiet fil-laboratorju li huma bbażati fuq interazzjoni bejn ilbijotina/streptavidin, li jwassal għal riżultati tat-testijiet li tnaqqsu b'mod falz jew li żdiedu b'mod falz, skont l-assaġġ.
English: The laboratory personnel should be consulted when ordering laboratory tests in patients taking biotin.
Maltese: Il-persunal tal-laboratorju għandu jiġi kkonsultat meta jkunu qed jiġu ordnati testijiet fil-laboratorju fil-pazjenti li jkunu qed jieħdu l-bijotina.
English: What you need to know before you take X
Maltese: X'għandek tkun taf qabel ma tieħu X
English: Alternative tests not susceptible to biotin interference should be used, if available, in cases where interference is suspected.
Maltese: Testijiet alternattivi li ma jkunux suxxettibbli għal interferenza tal-bijotina għandhom jintużaw, jekk ikunu disponibbli, f'każijiet fejn linterferenza hija ssuspettata.
English: Amlodipine: A randomized, blinded clinical trial in 9 cats with systemic hypertension.
Maltese: A randomized, blinded clinical trial in 9 cats with systemic hypertension.
English: Spontaneous feline hypertension: Clinical and echocardiographic abnormalities, and survival rate.
Maltese: Clinical and echocardiographic abnormalities, and survival rate.
English: Member State / EEA
Maltese: Stat Membru / ŻEE
English: The most frequently observed clinical signs were polyuria-polydipsia (34 %), heart murmur (28 %) and retinal detachment/haemorrhages (25 %).
Maltese: Issinjali kliniċi l-aktar osservati kienu polyuria-polydipsia (34 %), taħbit eċċessiv tal-qalb (heart murmur) (28 %) u distakk/emoraġiji retinali (25 %).
English: Ramipril is an angiotensin-converting enzyme (ACE) inhibitor.
Maltese: Ramipril huwa inibitur tal-enzim li jikkonverti l-anġjotensin (angiotensin-converting enzyme - ACE).
English: No statistical difference was observed in the distribution of clinical signs among cases when stratified by risk category (p=0.5296).
Maltese: L-ebda differenza statistika ma ġiet osservata fiddistribuzzjoni tas-sinjali kliniċi fost il-każijiet meta ġew mqassma skont il-kategorija tar-riskju (p=0.5296).
English: Snyder P.S.
Maltese: Snyder P.S. Amlodipine:
English: 0.125 mg/kg; 0.25 mg/kg if the animal does not respond after 2 weeks of
Maltese: 0.125 mg/kg; 0.25 mg/kg
English: 22 % (17 out of 76) of included cats had creatinine concentrations above the threshold.
Maltese: 22 % (17 minn 76) tal-qtates inklużi kellhom konċetrazzjonijiet ta' kreatinina ogħla mil-limitu.
English: J Vet Intern Med, 1999, 13.
Maltese: J Vet Intern Med, 1999, 13. P.
English: “For the reduction of elevated systolic blood pressure (between 160 and 230 mm Hg) and the control of associated clinical signs.”
Maltese: “Għat-tnaqqis tal-pressjoni sistolika tad-demm għolja (bejn 160 u 230 mm Hg) u l-kontroll tas-sinjali kliniċi assoċjati.
English: Belew A.M., Barlett T., Brown S.A.
Maltese: Belew A.M., Barlett T., Brown S.A. Evaluation of the white-coat effect in cats.
English: Vasotop P 0.625 mg, Vasotop P 1.25 mg and Vasotop P 2.5 mg tablets are veterinary medicinal products those contain the active ingredient ramipril at concentrations of 0.625 mg, 1.25 mg and 2.5 mg respectively.
Maltese: Il-pilloli Vasotop P 0.625 mg, Vasotop P 1.25 mg u Vasotop P 2.5 mg huma prodotti mediċinali veterinarji li fihom is-sustanza attiva ramipril f'konċentrazzjonijiet ta' 0.625 mg, 1.25 mg u 2.5 mg rispettivament.
English: • The MAH already had experience of having to abandon a placebo control group in a separate Chronic Renal Failure study, due to the unwillingness of owners to provide consent for treatment to be potentially withheld.
Maltese: • Il-MAH diġà kellu esperjenza fejn kellu jabbanduna grupp ta' kontroll bi plaċebo fi studju separat ta' Falliment Renali Kroniku, minħabba n-nuqqas ta' volontà tas-sidien li jagħtu lkunsens tagħhom biex it-trattament potenzjalment jitwaqqaf.
English: Around 33 % of the cases were between 160 and 180 mm Hg systolic blood pressure (risk category III) and 67 % ≥ 180 mm Hg systolic blood pressure (risk category IV) at inclusion.
Maltese: Madwar 33 % tal-każijiet kienu bi pressjoni sistolika tad-demm ta' bejn 160 u 180 mm Hg (kategorija ta' riskju III) u 67 % bi pressjoni sistolika tad-demm ta'≥ 180 mm Hg (kategorija ta' riskju IV) flinklużjoni.
English: The products are currently authorised for use in dogs for the treatment of congestive heart failure (NYHA classification grade II, III and IV) due to chronic degenerative valvular heart disease or cardiomyopathy, with or without adjunct diuretic (furosemide) or cardiac glycocide (digoxin/methyldigoxin) therapy.
Maltese: Il-prodotti huma attwalment awtorizzati għall-użu fil-klieb għat-trattament talfalliment tal-qalb konġestiv (klassifikazzjoni tal-NYHA tal-grad II, III u IV) minħabba mard talvalvoli tal-qalb deġenerattiv kroniku jew kardjomjopatija, flimkien ma' terapija dijuretika miżjuda (furosemide) jew bi glikosidi kardijaċi (digoxin/methyldigoxin) kif ukoll jekk le.
English: The mean CV was approximately 3 % at all time points studied; these values were similar to the CV values reported in the literature by Snyder
Maltese: Is-CV medju kien madwar 3 % fil-punti ta' żmien kollha studjati; dawn il-valuri kienu simili għall-valuri tas-CV irrapportati fiddokumentazzjoni minn Snyder
English: • The only prospective placebo-controlled study of feline hypertension reported that all 4 placebo cats were switched to the treatment group (amlodipine) after only 7 days (no reasons given - Snyder, 1998).
Maltese: • L-uniku studju prospettiv ikkontrollat bi plaċebo tal-pressjoni għolja tal-felini rrapporta li l-4 qtates bi plaċebo kollha tqiegħdu fil-grupp tat-trattament (amlodipine) wara 7 ijiem biss (ma ngħatat l-ebda raġuni - Snyder, 1998).
English: The average systolic blood pressure in cats with or without clinical signs at inclusion were in the same range (188.2 and 195.8 mm Hg, respectively), and were not statistically different (p=0.2132).
Maltese: 8 mm Hg, rispettivament), u ma kinux statistikament differenti (p=0.2132).